Cytoreductive nephrectomy vs medical therapy as initial treatment: A rational approach to the sequence question in metastatic renal cell carcinoma

Cancer Control

Volumn 17, Issue 4, 2010, Pages 269-278

  Spiess, Philippe E ^a   Fishman, Mayer N ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; EVEROLIMUS; INTERFERON; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN INHIBITOR;

ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; HUMAN; INDIVIDUALIZATION; INTERMETHOD COMPARISON; KIDNEY CANCER; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MEDICAL DECISION MAKING; MEDICAL LITERATURE; METASTASIS POTENTIAL; NEPHRECTOMY; OBESITY; OVERALL SURVIVAL; PATIENT CARE; PATIENT SELECTION; PRACTICE GUIDELINE; PROGNOSIS; TREATMENT PLANNING; TUMOR REGRESSION; TUMOR VOLUME;

EID: 77958599560     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481001700407     Document Type: Article

References (33)

1. Flanigan RC, Mickisch J, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171(3):1071-1076.
2. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530-2540.
3. Lara PN Jr, Tangen CM, Conlon SJ, et al. Southwest Oncology Group Trial S8949. Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. J Urol. 2009;181(2):512-516; discussion 516-517.
4. Lopez-Beltran A, Scarpelli M, Montironi R, et al. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006;49(5):798-805.
5. Méjean A, Oudard S, Thiounn N. Prognostic factors of renal cell carcinoma. J Urol. 2003;169(3):821-827.
6. Bonsib SM, Gibson D, Mhoon M, et al. Renal sinus involvement in renal cell carcinomas. Am J Surg Pathol. 2000;24(3):451-458.
7. Kim HL, Zisman A, Han KR, et al. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol. 2004;171(2 pt 1):588-591.
8. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22(3):454-463.
9. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312-3318.
10. Escudier B, Choueiri TK, Oudard S, et al. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol. 2007;178(5):1901-1905.
11. Vasselli JR, Yang JC, Linehan WM, et al. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol. 2001;166(1):68-72.
12. Escudier B., Eisen T, Stadler W et al. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. N Engl J Med. 2007;356(2):125-134.
13. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124.
14. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10(8):757-763.
15. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22): 2271-2281.
16. Logan T, McDermott D, Dutcher J, et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. Presented at the ASCO 2009 Genitourinary Cancers Symposium. Abstract 281.
17. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449-456.
18. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103-2111.
19. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33):5422-5428.
20. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061-1068.
21. Jonasch E, Wood CG, Matin SF, et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(25):4076-4081.
22. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol. 2003; 169(6):2076-2083.
23. Canfield SE, Kamat AM, Sánchez-Ortiz RF, et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol. 2006;175(3 pt 1):864-869.
24. Blom JH, van Poppel H, Maréchal JM, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol. 2009;55(1):28-34.
25. Kamat AM, Shock RP, Naya Y, et al. Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology. 2004;63(1):46-50.
26. Haferkamp A, Pritsch M, Bedke J, et al. The influence of body mass index on the long-term survival of patients with renal cell carcinoma after tumour nephrectomy. BJU Int. 2008;101(10):1243-1246.
27. Collins S, Pierorazio PM, McKiernan JM, et al. Fractional percentage of tumor volume removed is a predictor of outcome following cytoreductive nephrectomy for metastatic renal cell carcinoma. J Clin Oncol. 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2006;24(18S June 20 suppl):4599.Abstract.
28. Barbastefano J, Garcia JA, Elson P, et al. Association of percentage of tumor burden removed with debulking nephrectomy and progression free survival (PFS) in metastatic renal cell carcinoma (mRCC) patients (Pts) treated with VEGF-targeted therapy. Presented at the ASCO 2009 Genitourinary Cancers Symposium. Abstract 280.
29. Beck J, Bajetta E, Escudier B, et al. A large open-label, non-comparative phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Eur J Cancer Suppl. 2007;7:244. Abstract 4506.
30. Stadler WM, Figlin RA, McDermott DF, et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010;116(5):1272-1280.
31. Rathmell W, Cowey C, Amin C, et al. A pilot study of neoadjuvant sorafenib for the treatment of stage T2 or higher renal cell carcinoma. Presented at the ASCO 2009 Genitourinary Cancers Symposium. Abstract 315.
32. Wood CG. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res. 2007;13(2 pt 2):697s-702s.
33. Margulis V, Matin SF, Tannir N, et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008;180(1):94-98.